Cargando…

Insulin Therapy for Type 2 Diabetes

Detalles Bibliográficos
Autores principales:	Swinnen, Sanne G., Hoekstra, Joost B., DeVries, J. Hans
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Diabetes Progression, Prevention, and Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811456/ https://www.ncbi.nlm.nih.gov/pubmed/19875560 http://dx.doi.org/10.2337/dc09-S318

Ejemplares similares

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond
por: Bretzel, Reinhard G., et al.
Publicado: (2009)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Early Insulin Treatment in Type 2 Diabetes: What are the pros?
por: Meneghini, Luigi F.
Publicado: (2009)

Early Insulin Use in Type 2 Diabetes: What are the cons?
por: Chiasson, Jean-Louis
Publicado: (2009)

Nonpharmacologic Therapy and Exercise in the Prevention of Type 2 Diabetes
por: Tuomilehto, Jaakko
Publicado: (2009)

Combined Pharmacologic/Nonpharmacologic Intervention in Individuals at High Risk of Developing Type 2 Diabetes: Pro pharmacologic therapy
por: Garber, Alan J.
Publicado: (2009)

Changing the Treatment Paradigm for Type 2 Diabetes
por: Del Prato, Stefano, et al.
Publicado: (2009)

Defining and Characterizing the Progression of Type 2 Diabetes
por: Fonseca, Vivian A.
Publicado: (2009)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Antioxidant Anti-Inflammatory Treatment in Type 2 Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2009)

Goals of Treatment for Type 2 Diabetes: β-Cell preservation for glycemic control
por: Marchetti, Piero, et al.
Publicado: (2009)

Self-Monitoring of Blood Glucose as Part of the Integral Care of Type 2 Diabetes
por: Boutati, Eleni I., et al.
Publicado: (2009)

β-Cell Protection and Therapy for Latent Autoimmune Diabetes in Adults
por: Cernea, Simona, et al.
Publicado: (2009)

Where Does Insulin Resistance Start?: The brain
por: Pagotto, Uberto
Publicado: (2009)

Viewpoints on the Way to the Consensus Session: Where does insulin resistance start? The adipose tissue
por: Iozzo, Patricia
Publicado: (2009)

Viewpoints on the Way to a Consensus Session: Where does insulin resistance start? The liver
por: Perseghin, Gianluca
Publicado: (2009)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
por: Lebovitz, Harold E.
Publicado: (2011)

Telemedical Artificial Pancreas: PARIS (Páncreas Artificial Telemédico Inteligente) research project
por: de Leiva, Alberto, et al.
Publicado: (2009)

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2011)

Target for Glycemic Control: Concentrating on glucose
por: Monnier, Louis, et al.
Publicado: (2009)

Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration
por: Staels, Bart, et al.
Publicado: (2009)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
por: Miccoli, Roberto, et al.
Publicado: (2011)

Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes
por: Handelsman, Yehuda
Publicado: (2011)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Long-Term Benefits From Lifestyle Interventions for Type 2 Diabetes Prevention: Time to expand the efforts
por: Tuomilehto, Jaakko, et al.
Publicado: (2011)

Glucokinase Activators for Diabetes Therapy: May 2010 status report
por: Matschinsky, Franz M., et al.
Publicado: (2011)

A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs
por: Swinnen, Sanne G., et al.
Publicado: (2010)

Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes
por: Swinnen, S. G. H. A., et al.
Publicado: (2009)

Current Application of Continuous Glucose Monitoring in the Treatment of Diabetes: Pros and cons
por: Hermanides, Jeroen, et al.
Publicado: (2011)

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

Premeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes
por: Luijf, Yoeri M., et al.
Publicado: (2010)

Response to Comment on: Luijf et al. Premeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes. Diabetes Care 2010;33:2152–2155
por: Luijf, Yoeri M., et al.
Publicado: (2011)

Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naïve patients with type 2 diabetes
por: Naegeli, A N, et al.
Publicado: (2010)

Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
por: Cahn, Avivit, et al.
Publicado: (2016)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Incretin Effects on β-Cell Function, Replication, and Mass: The human perspective
por: Garber, Alan J.
Publicado: (2011)

Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vmp3knanjmgo7ib8hc9pt0qdoa